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The prevalence of atrial fibrillation is incre-
asing with aging population and with continuously
improving survival of patients with underlying car-
diovascular disorders [1]. Proper identification and
treatment of patients with atrial fibrillation is of
major importance to diminish cardiac and cardiova-
scular consequences of atrial fibrillation. Patients
with congestive heart failure and left ventricular
dysfunction are particularly predisposed to atrial
fibrillation since the underlying disease process fre-
quently contributes to pathology in atrial myocardium
and enlargement of atrial size [2–5]. Presence of chro-
nic atrial fibrillation in patients without evidence of
heart failure might successively lead to development
of signs of left ventricular dysfunction and symptoms
of heart failure.  Mechanistic links between heart fa-
ilure and atrial fibrillation may include: volume-rela-
ted atrial dilatation, increased dispersion of refracto-
riness in atria, catecholamine-induced atrial fibrosis,
and atrial channel remodeling [5–9].
Atrial fibrillation seems to influence the pro-
gnosis in heart failure patients although data are
controversial. In the SOLVD cohort [10] of 6517
patients with mean ejection fraction of 27%, atrial
fibrillation was found in 419 patients (6%). Atrial
fibrillation in this study was found to be significan-
tly associated with an increased risk of mortality,
congestive heart failure hospitalization, and also
arrhythmic death. In the data from the V-HeFT and
PRIME studies as well as in the PRIME II study,
atrial fibrillation was not an independent predictor
of mortality [11, 12]. In particular, the PRIME II
study [12], analyzed 409 patients with class III and
IV NYHA class heart failure and mean ejection frac-
tion of 23%, among which 84 patients (20%) had
atrial fibrillation. Atrial fibrillation was not found to
be an independent predictor of mortality after ad-
justment for clinical covariates in this cohort. The
MADIT II trial [13], which enrolled postinfarction
patients with low ejection fraction (£ 30%), showed
that atrial fibrillation was found in 8% of patients,
much lower percentage than in the PRIME II stu-
dy, however, the MADIT II had two-thirds of pa-
tients in NYHA class I and II.
There is more consistency in findings from
various prior studies regarding the association of
atrial fibrillation with risk of hospitalization for he-
art failure. Atrial fibrillation is an independent and
significant predictor of hospitalization for congesti-
ve heart failure, which was documented in all the
above quoted studies. For example, in the MADIT
II, atrial fibrillation at baseline was associated with
twice higher risk of hospitalization for heart failure
in comparison to patients in sinus rhythm.
In this issue of the journal, Grzybczak and co-
workers [14] presented interesting data regarding
the prognostic significance of atrial fibrillation
in a cohort of 152 patients with heart failure
(EF < 40%). Atrial fibrillation was identified in
relatively large proportion of 53 patients (35%),
although, it is worth emphasizing that paroxysmal
atrial fibrillation was present in 32 of these patients.
Therefore remaining 21 patients with persistent
atrial fibrillation reflect about 14% of the overall
studied population with predominantly NYHA class
III and mean EF in the range of 35%. As expected,
patients with AF had signs and symptoms of more
advanced heart failure. In this retrospective study, the
follow-up ranged from about 1 to 6 years, with mean
follow-up of about 3 years. Crude mortality rates
were higher in atrial fibrillation patients (28%) vs.
sinus rhythm patients (17%). Similarly to the men-
tioned above studies, Grzybczak et al. [14] could not
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confirm predictive value of atrial fibrillation for mor-
tality in the multivariate analysis. Importantly, the
authors evaluated separately cohorts of patients
with paroxysmal and persistent atrial fibrillation and
the crude mortality rates in the group with persi-
stent atrial fibrillation was 43% whereas group with
paroxysmal atrial fibrillation had rates similar (19%)
to those of sinus rhythm patients.
For comparison, a 2-year mortality rates in
MADIT II (EF £ 30%) patients (mostly persistent
atrial fibrillation patients) were found to reach 39%
whereas sinus rhythm patients had 20% 2-year
mortality rates [13]; therefore corresponding to
those found by Grzybczak et al. [14]. In both stu-
dies, multivariate analyses were dominated by age,
which no doubt is a strong predictor of mortality,
especially in patients with severe left ventricular
dysfunction. But age is not as clinically useful pre-
dictor as multivariate models suggest. Clinical me-
aning of atrial fibrillation and its consequences are
very relevant for clinical course of a given patient
much more than age per se. Twice higher mortality
rates in atrial fibrillation patients than in sinus rhy-
thm patients call for more aggressive approaches
in prevention and treatment of this difficult arrhy-
thmia. MADIT II data indicate that over 60% of
patients with atrial fibrillation reach endpoint of
hospitalization for heart failure or death. This very
high rate requires comprehensive treatment which
might require cardiac resynchronization therapy
and in increasing number of cases also ablation of
atrial fibrillation.  Cardiac resynchronization thera-
py in heart failure patients with atrial fibrillation
might require or probably should require atrio-ven-
tricular node ablation to obtain proper benefit of the
resynchronization of left ventricle.
Proper management of patients with chronic
atrial fibrillation requires maintaining acceptable
heart rate control. Satisfactory heart rate control
usually is defined when mean heart rate remains
below 80 bpm. Continuous tendency to tachycardia
in atrial fibrillation patients leads to deterioration
of hemodynamic parameters and development or
aggravation of heart failure. Several studies inclu-
ding the AFFIRM trial [15] demonstrated that rate
control results in a similar outcome to rhythm con-
trol in atrial fibrillation patients. However, the qu-
estion could be asked what parameters are sufficient
to determine proper rate control in atrial fibrillation
when rate of heart rate is very variable.
In this issue of the journal, Chudzik et al. [16]
describe experience with novel approach to rate
control by evaluating the coefficient of irregularity
of atrial fibrillation. Coefficient of irregularity is
defined as standard deviation of heart rate over
mean heart rate. Significant heart rate irregularity
is found when the coefficient of irregularity exce-
eds 0.20 [17]. Chudzik et al. [16] demonstrated that
in three quarters of studied patients who met cri-
teria for satisfactory rhythm control based on mean
heart rate < 80 bpm coefficient of irregularity had
abnormal values indicating insufficient rate control.
The verification of the findings by pacemaker me-
mory data in studied patients provides even further
evidence for the importance of monitoring heart
rate irregularity in addition to mean heart rate. As
pointed out by the authors, substantial number of
so called well-controlled atrial fibrillation patients
remains at increased risk of heart failure develop-
ment or progression.
Holter monitoring could be used to compute
coefficient of irregularity and since heart rate va-
riability calculation is included in all Holter systems,
physicians could start using heart rate variability
algorithms in atrial fibrillation patients. Currently,
SDNN, computed as part of heart rate variability
programs, is neglected by clinicians since it does
provide limited insight into the autonomic control
of the heart. The pioneering work by Chudzik and
coworkers [16] opens the door for practical usage
of SDNN and maybe RMSSD, assuming proper an-
notation of recordings. It needs to be further explo-
red whether coefficient of irregularity outperforms
SDNN or RMSSD in evaluating irregularities of
atrial fibrillation, i.e., whether the adjustment for
heart rate in the equation contributes to better il-
lustration of heart rate behavior in atrial fibrillation.
Nonlinear methods could also provide some insight
to the same phenomenon. Other questions which
need to be raised include the effect of pharmacolo-
gical agents on measured variation as well as the
prognostic significance of the coefficient regarding
the risk of progression of heart failure and risk of
cardiac events.
As always research begets research and both
studies, by Grzybczak et al. [14] and by Chudzik et
al. [16], open the list of questions which are to be
answered by new studies conducted by researchers
eager to get closer to the truth and to the optimal
patient management.
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